[1]
|
Isakoff, M.S., Bielack, S.S., Meltzer, P., et al. (2015) Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of Clinical Oncology, 33, 3029-3035. https://doi.org/10.1200/JCO.2014.59.4895
|
[2]
|
王显阳, 常君丽, 施杞, 等. 骨肉瘤相关信号通路的研究进展[J]. 中国癌症防治杂志, 2015, 7(1): 52-55.
|
[3]
|
Fidler, M.M., Frobisher, C., Guha, J., et al. (2015) Long-Term Adverse Outcomes in Survivors of Childhood Bone Sarcoma: The British Childhood Cancer Survivor Study. British Journal of Cancer, 112, 1857-1865.
https://doi.org/10.1038/bjc.2015.159
|
[4]
|
Allson, D.C., Carney, S.C., Ahlmann, E.R., et al. (2012) A Me-ta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era. Sarcoma, 2012, Article ID: 704872. https://doi.org/10.1155/2012/704872
|
[5]
|
Wu, P.K., Chen, W.M., Chen, C.F., et al. (2000) Primary Osteogenic Sarcoma with Pulmonary Metastasis: Clinical Results and Prognostic Factors in 91 Patients. Japanese Journal of Clinical Oncology, 30, 514-522.
https://doi.org/10.1093/jjco/hyp057
|
[6]
|
李汉忠, 张玉石, 郑国洋. 肿瘤免疫治疗: 回顾与展望[J]. 协和医学杂志, 2018, 9(4): 289-294.
|
[7]
|
黄志鹏, 宋科官. 骨肉瘤的诊断及治疗进展[J]. 国际骨科学杂志, 2018, 39(3): 150-153.
|
[8]
|
严海林. 骨肉瘤流行病学研究及术前风险评分模型的构建[D]: [博士学位论文]. 杭州: 浙江大学, 2017.
|
[9]
|
周四清, 毋凡, 王继峰, 等. 骨肉瘤的X线、CT、MRI影像对比诊断[J]. 实用医学杂志, 2009, 25(20): 3467-3468.
|
[10]
|
王玲, 王燕, 冯琛, 潘禹铮, 张英泽. 骨肉瘤免疫治疗的研究进展[J]. 中华老年骨科与康复电子杂志, 2017, 3(6): 381-384.
|
[11]
|
郑冠群, 赵福友, 吴穷, 杨燕. PD-1及其配体在骨肉瘤免疫治疗中的研究进展[J]. 中华全科医学, 2016, 14(9): 1560-1562.
|
[12]
|
孙保国, 陈泽雄, 张诗军, 刘泳冬, 黄红中, 尹丽荣. 复方中药对裸鼠肝癌模型PTEN蛋白表达的影响[J]. 中国中药杂志, 2007(11): 1057-1060.
|
[13]
|
Zheng, W.J., Xiao, H., Liu, H., et al. (2014) Expression of Programmed Death 1 Is Correlated with Progression of Osteosarcoma. APMIS, 123, 102-107. https://doi.org/10.1111/apm.12311
|
[14]
|
Simeone, E. and Ascierto, P.A. (2012) Immunomodulating Antibodies in the Treatment of Metastatic Melanoma: The Experience with Anti-CTLA-4, Anti-CD137 and Anti-PD1. Journal of Immunotoxicology, 9, 241-247.
https://doi.org/10.3109/1547691X.2012.678021
|
[15]
|
Lussier, D.M., Johnson, J.T., Hingorani, P., et al. (2015) Combination Immunotherapy with ɑ-CTLA-4 and ɑ-PD-L1 Antibody Blockade Prevents Immune Escape and Leads to Complete Control of Metastatic Osteosarcoma. Journal for Immunotherapy of Cancer, 3, 21. https://doi.org/10.1186/s40425-015-0067-z
|
[16]
|
Gobin, B., Battaglia, S., Lanel, R., et al. (2014) NVPBEZ235, a Dual PI3K/mTOR Inhibitor, Inhibits Osteosarcoma Cell Proliferation and Tumor Development in Vivo with an Improved Survival Rate. Cancer Letters, 344, 291-298.
https://doi.org/10.1016/j.canlet.2013.11.017
|
[17]
|
郑杰, 宋来君. 过表达HIF-1α和VEGF蛋白与垂体腺瘤侵袭行为的关系[J]. 现代肿瘤医学, 2018, 26(12): 1845-1848.
|
[18]
|
李桃英, 高珊珊, 刘鹏森, 朱宝菊. ER、VEGF、TGF-β1在增生期子宫内膜良恶性肿瘤中的表达及其相关性研究[J]. 实用癌症杂志, 2018, 33(3): 349-352.
|
[19]
|
谭胜, 王国祥. 外周血内VEGF水平对食管癌患者放化疗效果分析[J]. 北华大学学报(自然科学版), 2018, 19(1): 56-59.
|
[20]
|
Yu, X.W., Wu, T.Y., Yi, X., et al. (2014) Prognostic Significance of VEGF Expression in Osteosarcoma: A Meta-Analysis. Tumour Biology, 35, 155-160. https://doi.org/10.1007/s13277-013-1019-1
|
[21]
|
王东, 仲召阳, 李增鹏, 张沁宏, 何怡, 卿毅. 骨肉瘤VEGF表达及VEGF抗体抑制血管生成的实验研究[J]. 重庆医学, 2006(15): 1369-1372.
|
[22]
|
李龙. 抗血管内皮生长因子受体药物治疗晚期胃癌的Meta分析[D]: [硕士学位论文]. 兰州: 兰州大学, 2017.
|
[23]
|
Hu, Y., Wu, Z., Luo, Y., et al. (2017) Potent Anti-Leukemia Activities of Chimeric Antigen Re-ceptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. Clinical Cancer Research, 23, 3297-3306. https://doi.org/10.1158/1078-0432.CCR-16-1799
|
[24]
|
Locke, F.L., Neelapu, S.S., Bartlett, N.L., et al. (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 25, 285-295.
https://doi.org/10.1016/j.ymthe.2016.10.020
|
[25]
|
Gardner, R.A., Finney, O., Annesley, C., et al. (2017) In-tent-to-Treat Leukemia Remission by CD19 CAR T Cells of Defined Formulation and Dose in Children and Young Adults. Blood, 129, 3322-3331.
|
[26]
|
FDA (2017) FDA Approves CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm
|
[27]
|
Huang, X., Park, H., Greene, J., et al. (2015) IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS ONE, 10, e0133152. https://doi.org/10.1371/journal.pone.0133152
|
[28]
|
Liu, T., Ma, Q., Zhang, Y., et al. (2015) Interleukin-11 Receptor α Is Overexpressed in Human Osteosarcoma, and Nearinfrared-Labeled IL-11R α Imaging Agent Could Detect Osteosarcoma in Mouse Tumor Xenografts. Tumor Biology, 36, 2369-2375. https://doi.org/10.1007/s13277-014-2844-6
|
[29]
|
Suzuki, M. and Cheung, N.K. (2015) Disialoganglioside GD2 as a Therapeutic Target for Human Diseases. Expert Opinion on Therapeutic Targets, 19, 349-362. https://doi.org/10.1517/14728222.2014.986459
|
[30]
|
Bozzi, F., Tamborini, E., Negri, T., et al. (2007) Evidence for Activation of KIT, PDGFR Alpha, and PDGFR Beta Receptors in the Ewing Sarcoma Family of Tumors. Cancer, 109, 1638-1645. https://doi.org/10.1002/cncr.22587
|
[31]
|
Takagi, S., Takemoto, A., Takami, M., et al. (2014) Platelets Promote Osteosarcoma Cell Growth through Activation of the Platelet-Derived Growth Factor Receptor Akt Signaling Axis. Cancer Science, 105, 983-998.
https://doi.org/10.1111/cas.12464
|